Week in Review: Everest Announces Two In-Licensings with Total Value of $1 Billion
September 18, 2021 at 04:38 AM EDT
Deals and Financings Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Suzhou Sinovent and SinoMab Bio in a $561 million agreement; Everest also announced a $500 million deal for a mRNA COVID-19 vaccine and two other mRNA producs from Canada 's Providence Therapeutics; Cue Health, a San Diego company with China backers, filed for a $180 million US IPO to develop its home healthcare device, including a COVID-19 test; Haisco Pharma of Shannan in-licensed China rights to a novel osteoarthritis therapy from San Diego 's Biosplice in a $140 million agreement; IASO, a Nanjing biopharma, completed a $108 million Series C round to advance its novel cell therapy and biologic products; Alebund Pharma, a Shanghai company focused on renal diseases, closed a $54.5 million Series B+ financing round; Florida 's Cytovia established a Shanghai JV with an initial $45 million to develop its off-the-shelf CAR products in China ; Trials and Approvals Nanjing Legend Biotech was approved for a US Phase 1 trial of its autologous CD4 CAR-T lymphoma therapy; CStone Pharma of Suzhou will start China trials of its tri-specific immunotherapy, a next-gen anti-PD-1/PD-L1 that also targets 4-1BB and human serum albumin; Harbour BioMed was approved to start China trials of its next-gen CLTA-4/PD-1 candidate for hepatocellular and neuroendocrine carcinoma. Stock Symbols: (HK 1952) (HK: 3681) (SHZ: 002653) (NSDQ: LEGN) (HK: 2616) (HK: 02142) Share this with colleagues: // //